Drug Discovery Software Market Scope
Drug discovery software is used to develop new pharmaceutical drugs and test whether a newly created drug will be effective in treating a particular disease. Drug discovery software automates and leverages innovative technology that significantly cuts down on the arduous process of drug development, testing, and going to market. Most drug discovery solutions offer screening, predictive analytics, modeling, simulation, and computational capabilities. Those functionalities help with tasks such as image analysis and clinical trial results submission, as well as ensuring accurate reproducibility. Researchers and scientists use drug discovery software to gain market intelligence, take advantage of advancements in drug design and synthesis, tackle evolving and adapting diseases, and maintain and manage the integrity of data as drugs transition from the discovery phase to the clinical trial phase.
The market study is segmented, by Application (Pharmaceutical Industry and Biotechnology Industry) and major geographies with country level break-up.
Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Drug Discovery Software market throughout the predicted period.
Epocrates (United States), Thermo Scientific Nautilus LIMS (United States), ChemDraw (PerkinElmer) (United States), MicroTracker (Norway), DrugPatentWatch (United States), AutoDock (Scripps Research) (United States), Collaborative Drug Discovery Inc. (United States), DrugDev Spark (United States), DSG Drug Safety (United States) and PEPID PDC (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are Schrodinger Discovery Informatics Suite (United States), Advera Health (United States), American Gene Technologies (United States), Aurora Drug Discovery Software (United States) and BIOVIA Discovery Studio (United States).
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from total available market.
AdvanceMarketAnalytics has segmented the market of Global Drug Discovery Software market by Type, Application and Region.
On the basis of geography, the market of Drug Discovery Software has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).
Market Leaders and their expansionary development strategies
On 11 April 2019, Springer Nature and DrugPatentWatch partner to provide patent information for drug database. Newly available patent information supports researchers in their strategic decision-making in drug discovery. Drug patent information can help key stakeholders in the drug discovery process understand the impact of patent expiry on the competitive landscape, or their market share. They may also be able to evaluate licensing opportunities and explore what opportunities exist for drugs without patent protection, as well as develop end-of-life strategies for their products.
On 27 July 2017, Cyrus Biotechnology, Inc., a Seattle-based biotechnology software firm offering an advanced computational tool for protein modeling and design to accelerate new drug discovery, today announced the closing of an USD 8 million total Series A financing. The investment was led by Trinity Ventures, with participation from OrbiMed Advisors, SpringRock Ventures, W Fund and individual investors. Cyrus Bench software is based on years of work in computational biophysics and the first software algorithms to design new proteins in a computer. It accelerates drug discovery at pharmaceutical and biotechnology firms, as well as new product development at synthetic biology, chemical and consumer products firms.
- Rapidly Adoption of the Artificial Intelligence and Deep Learning Technology
- The Growing Pharmaceutical Industry Worldwide
- Surged R&D Activities in the Pharmaceutical Industry
- Growing Automation in the Drug Discovery Processes
- The Increasing Demand for the COVID-19 Drug Discovery
- The Upsurging Demand for the Drug Discovery Owing to the Expiration of Patents
- The Software Helps Pharmaceutical Companies to Remain Competitive In the Drug Market
- The Growing Demand for the Drug Discovery Software from the Asia Pacific Region
- Unknown Regulation Complications and Duplication Problems
Key Target AudienceDrug Discovery Software Key Companies, Potential Technology Investors, Regulatory & Government Bodies, Pharmaceutical Companies, Downstream Vendors and Others
Customization available in this Study:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase